Search Videos and More
Prostate Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2024.Study Highlights the Importance of Infection Prevention After CAR T-Cell Therapy
A systematic review and meta-analysis of non-relapse mortality after CAR T-cell therapy.Finding New Vulnerabilities in Uterine and Ovarian Cancers
Just like humans, cells get stressed, too — especially cancer cells. For decades, Dana-Farber researchers have been characterizing a complex molecular condition in cancer cells known as DNA replication stress.Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds
A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.2025 American Society of Clinical Oncology (ASCO)
Review video summaries and oral abstracts from Dana-Farber physician-scientists at the ASCO 2025 Annual Meeting.ASCO 2025: GU Highlights
In the following videos, Faculty from Dana-Farber Cancer Institute review GU Oncology highlights from the 2025 ASCO Annual Meeting, held in Chicago, May 30 - June 3, 2025.Disparities Research Symposium Focuses on Clinical Trials
Above all else, clinical research is about action – moving promising findings from the lab to patient care. The same can now be said about addressing disparities in clinical trial participation: that such disparities exist is well documented; the question going forward is how to reduce them.Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant abemaciclib in patients with early-stage, hormone-receptor-positive breast cancer.Adjuvant Ribociclib for Early-Stage Hormone Receptor-Positive Breast Cancer - Updated in 2025
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant ribociclib in patients with early-stage hormone receptor-positive breast cancer.Patients With a History of Breast Cancer who Desire Pregnancy
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.New Guidelines for Radiation Therapy for HPV-associated Head and Neck Cancer
Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: An ASTRO clinical practice guidelineAnti-inflammatory Drug Celecoxib Could Reduce Risk of Colon Cancer Recurrence for a Subset of Patients
Review analysis of data from a randomized clinical trial for patients with stage 3 colon cancer